Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.

[1]  R. Huddart,et al.  Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE). , 2020 .

[2]  R. Huddart,et al.  Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial , 2019, European urology.

[3]  A. Ravaud,et al.  Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial , 2019, Nature Medicine.

[4]  R. Bristow,et al.  Neoadjuvant Chemotherapy Before Bladder‐Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle‐Invasive Bladder Cancer , 2019, Clinical genitourinary cancer.

[5]  L. Mariani,et al.  Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[7]  A. Niemierko,et al.  Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. , 2017, European urology.

[8]  R. Huddart,et al.  BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer. , 2017 .

[9]  J. Witjes,et al.  MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .

[10]  T. Powles,et al.  Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer , 2015, Cancer.

[11]  R. Eeles,et al.  Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder , 2015, British Journal of Cancer.

[12]  R. Huddart,et al.  Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004) , 2013, International Journal of Radiation Oncology, Biology, Physics.

[13]  M. Parmar,et al.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Horwich,et al.  Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Michael W Kattan,et al.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[17]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[18]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Donnelly,et al.  Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03. , 1998, The Journal of urology.

[20]  Jacques Bernier,et al.  Late effects toxicity scoring: the SOMA scale , 1995 .

[21]  P. Rubin,et al.  RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system. , 1995, International journal of radiation oncology, biology, physics.

[22]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[23]  D. Tulsky,et al.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Galsky,et al.  The integration of chemotherapy and surgery for bladder cancer. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.